Patrick M. Moriarty, MD
Patrick M. Moriarty, MD is a Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas. He is the Director of Clinical Pharmacology and the Atherosclerosis andamp; Lipid-Apheresis Center. He earned his Doctorate in Medicine and Surgery at the University of Rome School of Medicine and Surgery in Italy and completed his residency in Internal Medicine and training in Clinical Pharmacology at the University of Kansas Medical Center.
Dr. Moriarty is a fellow of the American College of Physicians, the American College of Cardiology, the European Society of Cardiology, National Lipid Association and he was the 2014-2015 president of the International Society for Apheresis. He serves as a manuscript reviewer for multiple scientific journals and is the associate editor for the Journal of Clinical Apheresis and Clinical Lipidology.
Dr. Moriarty’s has published well over 100 peer reviewed articles/chapters. His research activities include such topics as atherosclerosis, familial hypercholesterolemia, Lp(a), Lipoprotein-Apheresis, vascular Inflammation, dementia and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, Lp(a), obesity, hypertension, and diabetes. Moreover, Dr. Moriarty is a member of the scientific advisory board for the FH Foundation. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipoprotein-Apheresis Center is the largest in North America for the treatment of Familial Hypercholesterolemia and elevated Lp(a).
Education and Training
- BA, St. Michael's Col.
- MD, Univ. di Roma
Licensure, Accreditations & Certifications
- Patrick M. Moriarty, MD, Kansas State Board of Healing Arts
- European Society of Cardiology, Fellow, 2019 - Present
- International Society for Apheresis, President, 2013 - 2015
- American College of Cardiology, Fellow, 2012 - Present
- American Heart Association, Member, 2012 - Present
- National Lipid Association, Fellow, 2012 - Present
- International Society for Apheresis, President Elect, 2011 - 2013
- International Society for Apheresis, Member, 2009 - Present
Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC, is a Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas. He is the Director of Clinical Pharmacology and the Atherosclerosis andamp; Lipoprotein-Apheresis Center. He has conducted over 100 clinical trials, and authored/co-authored over 100 articles, abstracts and chapters in peer review journals and books in the field of Lipids and Lipid-apheresis. He has served as the medical monitor for multi-site trials and is also a member of the Scientific advisory board for the Familial Hypercholesterolemia (FH) Foundation. Additionally, he is a fellow of the ESC, NLA, and ACC, and has served on several panels to develop guidelines regarding lipid management including the ACC/AHA recommendations for cholesterol management relating to alirocumab use, as well as the NHLBI working recommendations for the reduction of lipoprotein(a) due to its association with cardiovascular disease.
His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipid-Apheresis Center is the largest in North America for the treatment of Familial Hypercholesterolemia and elevated Lp(a). Dr. Moriarty is a fellow of the American College of Physicians, the American College of Cardiology, the European Society of Cardiology, National Lipid Association and he was the 2014-2015 president of the International Society for Apheresis.
His clinical background extends into his research efforts where he currently is the principal investigator on 13 clinical trials. Throughout his more than 20 year research tenure, Dr. Moriarty has served as Principal investigator on more than 100 trials, co-investigator on 6, and medical monitor on 2.
He serves as a manuscript reviewer for multiple peer-reviewed journals and is the associate editor for the Journal of Clinical Apheresis and Clinical Lipidology. His most notable publications of 2020 include:
Moriarty PM, Gorby LK, Stroes ES, Kastelein JP, Davidson M, Tsimikas S. Lipoprotein (a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: A Testable Hypothesis. Current Atherosclerosis Reports. 2020 Sep;22(9):1-8.
Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. Journal of Clinical Lipidology. 2020 Jan 13.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S. Lipoprotein (a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine. 2020 Jan 1.
Current Research and Grants
- A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects With Elevated Lipoprotein(a), Amgen, Inc
- A Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke, Amgen
- A Multicenter Open Label Single Arm Extension Study to Assess Long Term Safety of Evolocumab Therapy in Patients with Clinically Evident Cardiovascular Disease, Amgen Inc
- A Phase 1, Randomized, Double-blind, Placebo controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a), Amgen
- A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease, Novartis Pharmaceuticals
- A Randomized Pivotal Study of RenewTM NCP‐5 for the Treatment of Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type, Renew Research
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC - 1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease and who are Statin Intolerant (CLEAR-OUTCOMES), Esperion Therapeutics
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study if AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS), Ionis Pharmaceuticals, Inc
- A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients with Homzygous Familial Hypercholesterolemia., Regeneron Pharmaceuticals, Inc
- CASCADE FH Registry Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia, Duke University / Duke Clinical Research
- MEASURE: Metreleptin Effectiveness and Safety Registry, Aegerion Pharmaceuticals
- Tsimikas, S, Karwatowska-Prokopczuk, E, Gouni-Berthold, I, Tardif, J., C, Baum, S., J, Steinhagen-Thiessen, E, Shapiro, M., D, Stroes, E., S, Moriarty, P., M, Nordestgaard, B., G, Xia, S, Guerriero, J, Viney, N., J, O'Dea, L, Witztum, J., L. 2020. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.. The New England journal of medicine
- Moriarty, P., M, Thompson, P., D, Cannon, C., P, Guyton, J., R, Bergeron, J, Zieve, F., J, Bruckert, E, Jacobson, T., A, Baccara-Dinet, M., T, Zhao, J, Donahue, S. 2018. Efficacy and Safety of Alirocumab in Statin-Intolerant Patients Over 3 Years: Open-Label Extension of the ODYSSEY ALTERNATIVE Trial.
- Goldberg, A., C, Dunbar, R., L, Hemphill, L, Babi, S., P, Wilson, G, Wooten, M, Lydroose, M, Dacus, K, Minchew, H, Dutton, JA, Moriarty, P., M. 2020. A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients. Journal of Clinical Lipidology